A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty
Phase 4
Completed
- Conditions
- Corneal Transplantation
- Registration Number
- NCT00411515
- Lead Sponsor
- University Hospital Freiburg
- Brief Summary
The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty.
The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were immune reaction free and clear graft survival and the occurence of side-effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Keratoplasty with increased risk for immunologic graft rejection in the abscence of other risk factors for graft failure. (repeat keratoplasty, steroid-response, limbo-keratoplasty, oversized graft.
Exclusion Criteria
- Normal risk cases. Herpes-Keratitis. Glaucoma. Limbus stem cell deficiency.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Eye hospital
🇩🇪Freiburg, Germany
University Eye hospital🇩🇪Freiburg, Germany